[Clinical studies on urinary tissue polypeptide antigen (TPA): problems and improvement in determination]. 1989

M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
Department of Urology, Wakayama Medical College.

The reliability of measurement of urinary TPA using a Prolifigen TPA kit (Sangtec, Sweden) was investigated, and an improved method for stabilizing TPA was tested. Samples were filtrated with a cellulose nitrate membrane filter to remove impurities as a possible cause of a high false positive rate which has been a problem in urinary TPA measurement. Serum TPA and Tween 40-treated urinary TPA was not adsorbed by the filter, whereas TPA in the non-treated urine showed a marked affinity to the filter. This shows the instability of TPA in the original urine, and the impropriety of filtration as a measure of purification of urine samples. The dilution test of urine and the standard TPA, and the recovery test of the standard TPA added to 6 different urine samples showed reasonable results only when the samples were treated with Tween 40; otherwise the values were lower than expected. Thirty-four spot urine samples were tested to examine the change in TPA value during the storage for 24 hours. TPA values decreased when urine was stored at room temperature, but this change was prevented by treatment of urine with Tween 40.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011136 Polysorbates Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals. Polysorbate,Polysorbate 20,Polysorbate 80,Sorbitan Derivatives,Tween,Tweens,PSML,Polyoxyethylene Sorbitan Monolaurate,Tween 20,Tween 60,Tween 80,Tween 81,Tween 85,20s, Polysorbate,20s, Tween,60s, Tween,80s, Polysorbate,80s, Tween,81s, Tween,85s, Tween,Derivative, Sorbitan,Derivatives, Sorbitan,Monolaurate, Polyoxyethylene Sorbitan,Monolaurates, Polyoxyethylene Sorbitan,PSMLs,Polyoxyethylene Sorbitan Monolaurates,Polysorbate 20s,Polysorbate 80s,Sorbitan Derivative,Sorbitan Monolaurate, Polyoxyethylene,Sorbitan Monolaurates, Polyoxyethylene,Tween 20s,Tween 60s,Tween 80s,Tween 81s,Tween 85s
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011933 Reagent Kits, Diagnostic Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use. Diagnostic Reagent Kits,Diagnostic Reagents and Test Kits,Diagnostic Test Kits,In Vitro Diagnostic Device,In Vitro Diagnostic Devices,In Vitro Diagnostic Medical Device,In Vitro Diagnostic Medical Devices,Kits, Diagnostic Reagent,Diagnostic Reagent Kit,Diagnostic Test Kit,Kit, Diagnostic Reagent,Kit, Diagnostic Test,Kits, Diagnostic Test,Reagent Kit, Diagnostic,Test Kit, Diagnostic,Test Kits, Diagnostic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D019396 Tissue Polypeptide Antigen Serological tumor marker composed of a molecular complex of cytokeratins 8, 18, and 19. It is used in the diagnosis and staging of bronchogenic carcinoma. TPA Antigen,Antigen, TPA,Antigen, Tissue Polypeptide

Related Publications

M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
June 1984, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
December 1988, Hinyokika kiyo. Acta urologica Japonica,
M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
February 1984, Kaku igaku. The Japanese journal of nuclear medicine,
M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
September 1985, Gan no rinsho. Japan journal of cancer clinics,
M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
September 1985, Kaku igaku. The Japanese journal of nuclear medicine,
M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
December 1985, Hinyokika kiyo. Acta urologica Japonica,
M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
March 1984, Gan no rinsho. Japan journal of cancer clinics,
M Yoshida, and S Morimoto, and Y Uekado, and S Yasukawa, and H Aoshi, and T Yoshida, and S Ebisuno, and T Ohkawa
February 1977, Lakartidningen,
Copied contents to your clipboard!